



(11)

**EP 3 280 451 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(48) Corrigendum issued on:  
**25.09.2019 Bulletin 2019/39**

(45) Date of publication and mention  
of the grant of the patent:  
**14.08.2019 Bulletin 2019/33**

(21) Application number: **16717228.7**

(22) Date of filing: **07.04.2016**

(51) Int Cl.:  
**A61K 48/00** <sup>(2006.01)</sup> **A61P 25/28** <sup>(2006.01)</sup>  
**C12N 15/864** <sup>(2006.01)</sup>

(86) International application number:  
**PCT/US2016/026524**

(87) International publication number:  
**WO 2016/164642 (13.10.2016 Gazette 2016/41)**

(54) **VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER**

VIRALE GENTHERAPIE ZUR BEHANDLUNG VON  
CHOLESTERINSPEICHERUNGSEKANKUNG ODER -STÖRUNG

THÉRAPIE GÉNIQUE VIRALE À UTILISER EN TANT QUE TRAITEMENT POUR UNE MALADIE OU  
UN TROUBLE ASSOCIÉ AU STOCKAGE DU CHOLESTÉROL

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB  
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO  
PL PT RO RS SE SI SK SM TR**

(30) Priority: **08.04.2015 US 201562144702 P**

(43) Date of publication of application:  
**14.02.2018 Bulletin 2018/07**

(73) Proprietor: **The United States of America, as  
represented by  
the Secretary, Department of Health and Human  
Services  
Maryland 20892-7660 (US)**

(72) Inventors:  
• **VENDITTI, Charles, P.**  
**Kensington, MD 20895 (US)**  
• **PAVAN, William, J.**  
**Derwood, MD 20855 (US)**  
• **CHANDLER, Randy**  
**Washington, DC 20009 (US)**

(74) Representative: **Huenges, Martin**  
**Maiwald Patentanwalts- und  
Rechtsanwaltsgesellschaft mbH**  
**Elisenhof**  
**Elisenstraße 3**  
**80335 München (DE)**

(56) References cited:  
**WO-A1-2009/043936 WO-A1-2011/020118**  
**WO-A2-2012/061744**

- **C.A. PAUL ET AL: "Adenovirus expressing an NPC1-GFP fusion gene corrects neuronal and nonneuronal defects associated with Niemann pick type C disease", JOURNAL OF NEUROSCIENCE RESEARCH., vol. 81, no. 5, 1 September 2005 (2005-09-01), pages 706-719, XP055295101, US ISSN: 0360-4012, DOI: 10.1002/jnr.20592**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 3 280 451 B8**

- |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                       |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none"> <li>• Donald B Arnold ET AL: "A calcium responsive element that regulates expression of two calcium binding proteins in Purkinje cells (transcription&amp;#x35E;biolistic transfection&amp;#x35E;Ca 2? responses&amp;#x35E;calbindin&amp;#x35E;calmodulin II) Communicated by", Neurobiology May, 1 August 1997 (1997-08-01), pages 8842-8847, XP055295089, Retrieved from the Internet: URL:<a href="http://www.pnas.org/content/94/16/8842">http://www.pnas.org/content/94/16/8842</a> .full.pdf [retrieved on 2016-08-11]</li> </ul> | <ul style="list-style-type: none"> <li>• T D BARBARA NGUYEN-VU ET AL: "Cerebellar Purkinje cell activity drives motor learning", NATURE NEUROSCIENCE, vol. 16, no. 12, 27 October 2013 (2013-10-27), pages 1734-1736, XP55295269, US ISSN: 1097-6256, DOI: 10.1038/nn.3576</li> </ul> |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|